La cadena de opciones muestra datos clave de las opciones de acciones de Cue Biopharma a varios precios de ejercicio y fechas de vencimiento. Los operadores utilizan esta información para analizar posibles operaciones y evaluar el sentimiento del mercado para Cue Biopharma..

Cue Biopharma (NASDAQ:CUE) Bolsa, Cadena de Opciones

Cue Biopharma

Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune disease with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103 and others.

Cue Biopharma Inc

Cuentas Inc

COPPEREX RES CORP by COPPEREX RES CORP

CUE ENERGY RESOURCES LTD by Cue Energy Resources Ltd.

Piper Sandler analyst Mark Lear maintains Occidental Petroleum (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OXY#NYSE">OXY</a>) with a Neutral and lowers the price target from $51 to $50.

News

Price Target

Analyst Ratings

Piper Sandler Maintains Neutral on Occidental Petroleum, Lowers Price Target to $50

Organovo Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ONVO#NASDAQ">ONVO</a>) ("Organovo" or the "Company"), a clinical stage biotechnology company focused on developing novel treatment approaches in inflammatory bowel disease (IBD) today announced it has issued additional shares in conjunction with warrant exercises by investors and at-the-market stock sales. An additional 2,967,144 shares of common stock of the Company have been issued. The shares of common stock issuable upon exercise of the outstanding warrants were registered pursuant to a registration statements that was declared effective on May 8, 2024. The aggregate gross proceeds from the exercise of the existing warrants and at-the-market stock sales are expected to total approximately $2.3 million, before deducting financial advisory fees and commissions. After giving effect to the issuance of these additional shares, the Company has 20,421,617 shares of outstanding common stock.

Offerings

ONVO

Organovo Holdings Issues 2,967,144 Additional Shares Through Warrant Exercises and At-The-Market Stock Sales, Raising ~$2.3M In Gross Proceeds, Bringing Total Outstanding Shares to 20,421,617

Piper Sandler analyst Mark Lear maintains Murphy Oil (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MUR#NYSE">MUR</a>) with a Overweight and lowers the price target from $35 to $34.

Piper Sandler Maintains Overweight on Murphy Oil, Lowers Price Target to $34

-- The Simple, No-cost Test Can Detect Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) Autoantibodies in the Blood with Only a Finger Prick --
<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fsavarapharma.com%2F&amp;esheet=54219866&amp;newsitemid=20250306574544&amp;lan=en-US&amp;anchor=Savara+Inc.&amp;index=1&amp;md5=7869700ed793696d9f0296d20b4454f8">Savara Inc.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SVRA#NASDAQ">SVRA</a>) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, announced the launch of the aPAP ClearPath Dried Blood Spot (DBS) Test in the U.S., an evolution of the first serum-based assay the Company launched. The DBS test helps obtain a diagnosis of aPAP, a rare autoimmune lung disease caused by antibodies targeting GM-CSF, with only a finger-prick blood sample.
The DBS test demonstrates a high correlation between GM-CSF autoantibody levels in dried serum and traditional serum samples, ensuring reliable results, and has achieved 100% analytical sensitivity and specificity in a cohort of individuals with confirmed GM-CSF autoantibody status. The Company partnered with TrilliumBiO, a health solutions provider with a Clinical Laboratory Improvement Amendments (CLIA)-certified lab, to develop and validate the simple, no-cost, and noninvasive test.

Biotech

General

SVRA

Savara Announces U.S. Launch Of The aPAP ClearPath Dried Blood Spot Test To Detect Autoimmune Pulmonary Alveolar Proteinosis

Piper Sandler analyst Mark Lear maintains Expand Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXE#NASDAQ">EXE</a>) with a Neutral and raises the price target from $96 to $101.

Piper Sandler Maintains Neutral on Expand Energy, Raises Price Target to $101

&nbsp;
- ARO-INHBE and ARO-ALK7 both target a known pathway that signals the body to store fat in adipose tissue with a novel mechanism of action that may better preserve lean muscle mass compared to currently approved obesity therapies
- Data highlight Arrowhead's leadership in the use of RNA interference to potentially treat Obesity

Events

ARWR

Arrowhead Pharmaceuticals Presents Preclinical Data Supporting ARO-INHBE and ARO-ALK7 To Treat Obesity And Metabolic Diseases

Piper Sandler analyst Mark Lear maintains EQT (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EQT#NYSE">EQT</a>) with a Neutral and raises the price target from $35 to $36.

Piper Sandler Maintains Neutral on EQT, Raises Price Target to $36

WIIM

Ohmyhome shares are trading lower after the company announced a 1-for-10 reverse stock split to be effective on March 10.

Explore what deepfake creators are doing to evade detection, the impact of generative AI on deepfakes, the escalating threats in cybersecurity, and mitigation tactics to combat AI-driven fraud
DENVER, March 06, 2025 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=rFOHMcqj_xFshal7LipmCBFFFJt5e8DlWGtVp-ynloq1_reYS16SU_A_1imtT7IO">authID</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AUID#NASDAQ">AUID</a>), a leading provider of biometric identity verification and authentication solutions, today released a comprehensive whitepaper detailing innovative approaches to combat the rising threat of deepfake fraud in digital authentication systems. The whitepaper, titled "Deepfake Countermeasures," provides crucial insights into deepfakes as the next generation in fraud attacks, as well as cutting-edge defensive strategies against presentation and injection attacks.
The increasing sophistication of AI platforms means attackers can use a single photo to synthesize deepfake videos. authID's report presents a critical framework for organizations to protect against a spike in identity fraud attempts and leverages authID's proprietary multi-layered detection system, which achieves a billion-to-one false-match accuracy rate. authID's platform detects the liveness of each authentication attempt, preventing the use of pictures, videos and deepfakes for spoofing identities, known as presentation attacks.

AUID

authID Publishes New Whitepaper On Next-Generation Deepfake Detection Technology Titled "Deepfake Countermeasures"

CYCU

Cycurion Partners With CentralSquare Technologies To Provide Public Safety IT Services

Piper Sandler analyst Mark Lear maintains EOG Resources (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EOG#NYSE">EOG</a>) with a Neutral and lowers the price target from $141 to $135.

Piper Sandler Maintains Neutral on EOG Resources, Lowers Price Target to $135

ZyVersa Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZVSA#NASDAQ">ZVSA</a>, or "ZyVersa"))), a clinical stage specialty biopharmaceutical company developing first-in-class drugs for treatment of inflammatory and renal diseases, today announced that it has entered into a securities purchase agreement with a single healthcare-focused U.S. institutional investor for the purchase and sale of 2,105,265 shares of common stock (or common stock equivalents in lieu thereof) and warrants to purchase up to 2,105,265 shares of common stock at an effective combined price of $0.95 per share and common warrant for aggregate gross proceeds of approximately $2.0 million, before deducting placement agent fees and other offering expenses. The warrants will have an exercise price of $1.00 per share, will be exercisable immediately upon shareholder approval and will expire five years from the initial exercise date.
The closing of the offering is expected to occur on or about March 7, 2025, subject to the satisfaction of customary closing conditions. The Company expects to use the net proceeds from the offering for general working capital.
A.G.P./Alliance Global Partners is acting as the sole placement agent in connection with the transaction.

ZVSA

ZyVersa Therapeutics Announces Pricing Of $2M Private Placement Priced At The Market

Adds to Extensive Preclinical and Early Clinical Evidence that Nebokitug Interferes with Key Features&nbsp; of Systemic Sclerosis &nbsp;
TEL AVIV, Israel, March 06, 2025 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=7iF72dYqYIForA9mYcGm2LioRkwJo-D8darEBq2CyCSJdVooMoRIrOJIfUAPi3gadSYKb144QxsjXCtgJMQWuMo1xSfGTSctxDdvzOyvSgM=">Chemomab Therapeutics, Ltd</a>. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMMB#NASDAQ">CMMB</a>), a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammatory diseases with high unmet need, today announced a new scientific presentation that further confirms the potential of nebokitug (CM-101) as a novel treatment for systemic sclerosis (SSc).1 The data will be presented at the <a href="https://www.globenewswire.com/Tracker?data=96J9V9lZEEXaaV4s9q1tzEexR1fMKSwwgereOBqnmCVF1xwKqCBsiRcUvSGYYD1NBd2mwDXtXUDcoHSH_MojM8L6_L5OYnR2XA0hBT0Y_9VKzH0WWY013rp0cutDL663VkqvKwTzSCweluKIY4Hmp9LDhTDoyO3UmPZLfVh_Bkg=">8th International Congress on Controversies in Rheumatology and Autoimmunity</a> (CORA 2025) on March 8, 2025, in Venice, Italy.
Systemic sclerosis is an autoimmune disease characterized by microvascular injury and extensive tissue fibrosis of the skin and internal organs. It is the most lethal of the systemic connective tissue diseases and lacks approved disease-modifying therapies. Nebokitug is a first-in-class monoclonal antibody that blocks the soluble protein CCL24, which has been shown to be a key driver of the pathways underlying fibro-inflammatory conditions such as SSc and primary sclerosing cholangitis (PSC). In extensive preclinical studies, blocking CCL24 reduced the inflammatory and fibrotic injury to the lung, skin and vasculature that are hallmarks of SSc pathology. An investigator-sponsored study showed that treatment with nebokitug induced strong and rapid reductions in inflammatory biomarkers in patients with acute lung Injury, a relevant model for the type of lung damage seen in SSc patients.

Chemomab Therapeutics Ltd. - American Depositary Shares

CMMB

Chemomab Therapeutics Presents New Data Highlighting Clinical Potential Of Its Nebokitug In Systemic Sclerosis At CORA 2025 Conference

Lakeside Holding shares are trading higher after the company announced convertible debt financing of up to $4.5 million.

Piper Sandler analyst Mark Lear maintains Coterra Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CTRA#NYSE">CTRA</a>) with a Overweight and raises the price target from $34 to $37.

CTRA

Piper Sandler Maintains Overweight on Coterra Energy, Raises Price Target to $37

Guidance

Macy's CEO Says Consumers Remain Under Pressure Navigating From An Inflation Rate And Yet Wanting To Indulge At Times; Says 'I Don't Think The Consumer Is Going To Feel A Sense Of Relief In The Short Term'

<ul>
<li>Proactive steps reinforce bioAffinity Technologies' laser focus on accelerating CyPath&#xAE; Lung sales growth in strategic national markets</li>
<li>Decreases labor and overhead costs, including 38% workforce reduction in non-CyPath&#xAE; Lung personnel at Company's subsidiary laboratory</li>
</ul>
<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fbioaffinitytech.com%2F&amp;esheet=54220116&amp;newsitemid=20250306388376&amp;lan=en-US&amp;anchor=bioAffinity+Technologies&amp;index=1&amp;md5=35df396edda935fc0a25014d8944a15f">bioAffinity Technologies</a>, Inc. (NASDAQ:<a href="https://www.benzinga.com/stock/BIAF#NASDAQ">BIAF</a>, BIAFW)), a biotechnology company focused on the need for noninvasive tests for the detection of early-stage lung cancer and other lung diseases, today announced targeted strategic actions to improve financial performance and accelerate the commercial growth of <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.cypathlung.com&amp;esheet=54220116&amp;newsitemid=20250306388376&amp;lan=en-US&amp;anchor=CyPath%26%23174%3B+Lung&amp;index=2&amp;md5=a255ade8a66b4dc2743693184fe3bafd">CyPath&#xAE; Lung</a>, the Company's noninvasive test for early-stage lung cancer. The Company expects these measures to deliver approximately $4 million in annual cost savings at its subsidiary Precision Pathology Laboratory Services (PPLS), while increasing resources to expand CyPath&#xAE; Lung sales in high-potential national markets.

BIAF

bioAffinity Technologies Announces Targeted Strategic Actions To Improve Financial Performance And Accelerate The Commercial Growth Of CyPath Lung; Expects These Measures To Deliver ~$4M In Annual Cost Savings

Macy's CFO Says For Q1 Expect These Pressures Along With Inflation And Tariffs To Continue

Organovo shares are trading higher after the company announced issuance of additional shares.

Piper Sandler analyst Mark Lear maintains Civitas Resources (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CIVI#NYSE">CIVI</a>) with a Overweight and lowers the price target from $71 to $66.

CIVI

Piper Sandler Maintains Overweight on Civitas Resources, Lowers Price Target to $66

Management

Press Releases

Cue Biopharma Appoints Industry Veteran Lucinda Warren as Chief Business Officer

Financing

Cue Biopharma Announces Proposed Public Offering

Cue Biopharma Announces Pricing of $12.0 Million Public Offering

Cue Biopharma Announces Upcoming Scientific Presentations at the Society for Immunotherapy of Cancer's (SITC) 39th Annual Meeting

Health Care

Cue Biopharma Presents Positive Updated Data from its Phase 1 Trials of CUE-101 and CUE-102 in Head and Neck Cancer and WT1 Positive Cancers at the SITC 39th Annual Meeting

Comments

Cue Biopharma

Cue Biopharma (CUE) Opciones

Cue Biopharma (NASDAQ:CUE) Bolsa, Cadena de Opciones

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL